Eurosurveillance banner


Today Eurosurveillance is publishing a special issue dedicated to the widespread advances made in Europe in estimating the real number of newly acquired HIV infections based on an innovative approach called STARHS

To tie in with World Hepatitis Day on 19 May, the scientific journal Eurosurveillance is today publishing a special issue on viral hepatitis, highlighting issues and challenges related to hepatitis B and C.

On 17 April 2008, Eurosurveillance is publishing a special issue with articles on the measles situation in Europe. The publication is linked to European Immunisation Week which runs from 21-27 April.

World Tuberculosis Day on 24 March commemorates the date in 1882 when Robert Koch presented his findings of the causing agent of tuberculosis (TB) – Mycobacterium tuberculosis. In the run up of this day Eurosurveillance publishes a special issue on the situation of TB in Europe.

Today (6 March, 2008), Eurosurveillance, the European peer-reviewed journal of infectious diseases, publishes a special issue on meningococcal disease. It includes two in-depth articles and an editorial by the European Centre for Disease Prevention and Control (ECDC).


In this issue


Home Eurosurveillance Monthly Release  2001: Volume 6/ Issue 1 Article 2 Printer friendly version
Back to Table of Contents
en es fr it pt
Previous Next

Eurosurveillance, Volume 6, Issue 1, 01 January 2001
Articles
EARSS activities and results: update

Citation style for this article: Buchholz U, Bronzwaer SL, Schrijnemakers P, Monen J, Kool JL. EARSS activities and results: update. Euro Surveill. 2001;6(1):pii=226. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=226
U. Buchholz, S.L.A.M. Bronzwaer, P. Schrijnemakers, J. Monen, J.L. Kool, and EARSS participants (see annex)
National Institute of Public health and the Environment, Bilthoven, the Netherlands

The latest EARSS results (1990–2000) suggest that the rates of methicillin resistant S. aureus and Penicillin Non Susceptible S. pneumoniae are higher in southern European countries than in the North. Young children, followed by elderly people are the most at risk for an infection by PNSP. The risk to be infected by methicillin resistant S. aureus increases with age, patients hospitalised in intensive care units being more exposed to that risk.

The European Antimicrobial Resistance Surveillance System (EARSS), funded by the European Commission, is a network of national surveillance systems aiming to collect comparable resistance data (1). What is the status and what are the present contributions of EARSS to the surveillance systems of its Member Countries, and to the surveillance of antimicrobial resistance in Europe in general?

The number of countries reporting to EARSS has increased from 14 in 1999, to 18 in 2000 (with Austria, Bulgaria, the Czech Republic, and Malta also reporting), and is expected to rise to 24 in 2001. At the moment, EARSS monitors two pathogens: Streptococcus pneumoniae and Staphylococcus aureus. In November, the plenary assembly of EARSS member countries decided to include new pathogens: Escherichia coli and E. faecium/E. faecalis. EARSS reflects on a wider scale what is being done at national levels. The quality of data reported to EARSS has been inspected extensively by setting up quality control filters by the EARSS Management Team and national representatives. Improvements have been made where necessary. For example, reporting procedures have been further standardised, reporting deadlines have been introduced, and timeliness of reporting has improved considerably. This is the result of a common effort of all countries. Furthermore, many Member Countries where reporting still takes place through paper forms have moved closer to electronic reporting. On the microbiological side, EARSS in collaboration with NEQAS (National External Quality Assessment System - UK) has collaborated with 482 laboratories to test the comparability of susceptibility test results across countries and interpretation guidelines. The response was high, at 90%, which confirms the commitment of laboratories to quality. Moreover, the comparability of susceptibility test results was satisfactory. Detailed results of the exercise will be published soon on the EARSS web site (http://www.earss.rivm.nl).

We present a summary of results based on the collection of resistance data from invasive strains of S. pneumoniae since 1998 to present (2, 3). In this context ‘penicillin non-susceptible S. pneumoniae‘ (PNSP) is of primary importance. Since 1998, 16 countries have contributed data from in total 7108 invasive S. pneumoniae isolates (table 1). In EARSS the term ‘invasive’ refers to blood and cerebrospinal fluid isolates only. Most specimens (92%) appear to come from blood. As some patients may have an isolate from blood and cerebrospinal fluid, and first isolates only are reported, this proportion could be somewhat different. There is a preponderance of males (57%) among the patients with invasive S. pneumoniae.

Table. Cumulative susceptibility test results of invasive S. pneumoniae and S. aureus from all countries that reported since 1998

Country

PNSP

S. pneumoniae

% PNSP

MRSA

S. aureus

%MRSA

I

R

Austria

0

0

33

0

33

153

22

Belgium

143

85

1531

15

132

602

22

Bulgaria

0

0

5

0

22

61

36

Czech Republic 

2

0

44

5

5

82

6

Germany

0

1

210

0

54

633

9

Denmark

10

1106

1

Spain

316

124

1344

33

254

707

36

Finland

8

7

246

6

3

461

1

Greece

196

554

35

Irland

28

14

265

16

324

812

40

Iceland

2

0

77

3

1

58

2

Italy

13

27

338

12

674

1615

42

Luxembourg

1

1

27

7

7

65

11

Malta

0

0

5

0

13

35

37

Netherlands

11

4

1106

1

8

1777

0

Portugal

20

0

119

17

136

369

37

Sweden

18

4

1214

2

14

1917

1

United Kingdom 

16

20

544

7

507

1385

37

PNSP = penicillin non-susceptible S. pneumoniae ; I = intermediate resistant; R = resistant ; SARM  =  methicillin resistant S. aureus.
To explore the relative incidence of invasive isolates in the different age groups adjusting for country, we used Poisson regression, with the (log) population as the offset and country and age group (0-4, 5-14, 15-64, >64) as covariables. The figure shows that elderly people have the highest relative incidence, then infants and toddlers, followed by teenagers and adults.
We also examined the likelihood of a resistance in the four age groups as indicated above given an invasive strain of S. pneumoniae was cultured. We used logistic regression to control for the impact of country, and took the age group of the elderly as the reference. As the figure shows, young children are the age group with the highest risk for resistance (odds ratio 1.5; 95% confidence interval 1.2 to 1.9) followed by elderly people (reference group). Teenagers (0.6; 0.4 to 1,0) and adults (0.6; 0.5 to 0.7) have the lowest risk.

The proportion of PNSP is in general higher in southern Europe compared with northern European countries. We calculated a half yearly overall proportion of resistance weighted by the size of the population of each country, starting in 1999. The overall proportion of PNSP in Europe remained fairly stable (January to June 1999: 10%, July to December 1999: 10%, January to June 2000: 12%).

Methicillin resistant S. aureus

Since 1998, a total of 18 countries have reported blood isolates of S. aureus to EARSS. Similar to S. pneumoniae, the number of reporting laboratories in various countries varies greatly among countries due to differences in the size of population, the healthcare organisation, and the coverage of the surveillance system. Since most laboratories are associated with only one hospital, the number of hospitals also varies widely between countries. S. aureus is largely a problem associated with hospital stay, and it is therefore particularly important to include in each country a representative sample of hospitals from different sizes and functions, covering all geographical areas. Some countries are continuing in their efforts to improve the representativeness of the laboratories and hospitals participating.

In almost every country exactly 60% of the isolates are from male patients. Male sex is, however, no risk factor for MRSA. We divided the departments of the patients’ stay into two groups: adult or paediatric intensive care unit (ICU) versus other wards, such as the internal medical or obstetric and gynaecologic department. Compared with patients in the second group, patients from an ICU were 2.3 times more likely to have a S. aureus strain that was resistant to methicillin.

In a multivariate model we included the variables age (for four groups: 0-4, 5-14, 15-64, >64 years of age) and hospital department, controlling for country. Both age and hospital department remained significant predictors. In contrast to S. pneumoniae, the risk of identifying an MRSA strain given S. aureus was cultured from blood, rises with increasing age. Children aged 0-4 years and children aged 5-14 years are only 0.1 times, whereas are adults 0.6 times as likely as elderly people (reference) to be infected with MRSA.

Finally, we examined the proportion of hospitals reporting MRSA to EARSS over time. The proportion of hospitals reporting at least one MRSA rose from 40% in January to June 1999 to 49% in July to December 1999, to stabilise with 47% during January to June 2000. It is too early to comment on a possible trend, because the observed period of time is still relatively short and there are still new countries joining EARSS.

A comparison of proportions of MRSA among different European countries (table) suggests that the proportion is higher in southern Europe. For both PNSP and MRSA, however, these differences may in part be due to different testing behaviours or attitudes among physicians.

Annex. Participating countries and national representatives in EARSS

Austria -  H. Mittermayer, W. Koller Israël - R. Raz
Belgium -  H. Goossens, F. van Loock Italy -  G. Cornaglia, M.L. Moro
Bulgaria  -  B. Markova Luxembourg - R. Hemmer
Czech Republic -  P. Urbaskova Malta -  M. Borg
Denmark -  T. L. Sørensen, D. Monnet Netherlands -  A.J. de Neeling, W. Goettsch
Finland -  P. Huovinen, O. Lyytikäinen Norway -  E. Hoiby, P. Aavitsland
France - P. Courvalin, H. Aubry-Damon Poland -  V. Hryniewicz
Germany -  W. Witte, T. Breuer Portugal - M. Caniça, M. Paixão
Greece -  N. Legakis, A. Vatopoulos Slovenia -  M. Gubina
Hungary -  M. Konkoly-Thege Spain -  F. Baquero, J. Campos
Iceland -  K. Kristinsson, H. Briem Sweden -  B. Olsson-Liljequist, O. Cars
Ireland -  O. Murphy, D. O’Flanagan United Kingdom -  A. Johnson, M. Wale

References
  1. Bronzwaer SLAM, Goettsch W, Olsson-Liljequist B, Wale MCJ, Vatopoulos AC, Sprenger MJW. European Antimicrobial Resistance Surveillance System (EARSS): objectives and organisation. Eurosurveillance 1999; 4: 41
  2. Goettsch W, Bronzwaer SLAM, Neeling de AJ, Wale MCJ, Aubry-Damon H, Olsson-Liljequist B, Sprenger MJW, Degener JE. Standardisation and quality assurance for antimicrobial resistance of Streptococcus pneumoniae and Staphylococcus aureus within the European Antimicrobial Resistance Surveillance System (EARSS). CMI 2000; 6; 59-63
  3. Veldhuijzen I, Bronzwaer S, Degener J, Kool J, EARSS participants, European Antimicrobial Resistance Surveillance System (EARSS): susceptibility testing of invasive Staphylococcus aureus. Eurosurveillance march 2000;vol.5, nr.3;34-35

 



Back to Table of Contents
en es fr it pt
Previous Next

Disclamer:The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the Editorial team or the institutions with which the authors are affiliated. Neither the ECDC nor any person acting on behalf of the ECDC is responsible for the use which might be made of the information in this journal.
Eurosurveillance [ISSN] - ©2008 All rights reserved